![Marcelo Bravo](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Marcelo Bravo
Vorstandsvorsitzender bei OXvax Ltd
Aktive Positionen von Marcelo Bravo
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Oxford Pharmascience Ltd.
![]() Oxford Pharmascience Ltd. Pharmaceuticals: MajorHealth Technology Oxford Pharmascience Ltd. operates as a drug development firm. The company was founded on February 8, 2008 and is headquartered in London, the United Kingdom. | Direktor/Vorstandsmitglied | 08.02.2008 | - |
OXvax Ltd
![]() OXvax Ltd BiotechnologyHealth Technology OXvax Ltd is a British company that develops cancer vaccines. The company was founded in 2021 by Paul J. Fairchild, Marcelo Leonardo Bravo, Tim Davies. Marcelo Leonardo Bravo has been the CEO since 2021. | Vorstandsvorsitzender | 15.02.2021 | - |
Gründer | 15.02.2021 | - |
Karriereverlauf von Marcelo Bravo
Ehemalige bekannte Positionen von Marcelo Bravo
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
DEEPMATTER GROUP PLC | Direktor/Vorstandsmitglied | - | 01.10.2009 |
Präsident | - | 01.10.2009 | |
ABACO CAPITAL PLC | Gründer | 07.10.2009 | - |
Ausbildung von Marcelo Bravo
Case Western Reserve University | Undergraduate Degree |
London Business School | Graduate Degree |
The College of Wooster | Undergraduate Degree |
Statistik
International
Vereinigtes Königreich | 6 |
Vereinigte Staaten | 3 |
Operativ
Director/Board Member | 2 |
Founder | 2 |
Undergraduate Degree | 2 |
Sektoral
Consumer Services | 4 |
Health Technology | 3 |
Technology Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 4 |
---|---|
DeepMatter Group Plc
![]() DeepMatter Group Plc Packaged SoftwareTechnology Services DeepMatter Group Plc is engaged in the development of a number of projects targeting new chemicals, materials, formulations, and pharmaceuticals in commercial areas. It operates through the following segments: DeepMatter and InfoChem. The DeepMatter segment owns, develops and is in the early stage of exploiting intellectual property, software, hardware and data analysis capabilities combined as a visionary, disruptive platform called DigitalGlassware, enabling step changes in productivity and discovery for scientists in the pharma and life science sectors. The InfoChem segment develops and commercialises cheminformatics software to handle, store and retrieve chemical structures and reactions for application in pharma, life sciences, and scientific publications. The company was founded by Jon-Paul Griffiths and Mark G. Moloney on June 13, 2006 and is headquartered in Glasgow, the United Kingdom. | Technology Services |
Abaco Capital Plc
![]() Abaco Capital Plc Financial ConglomeratesFinance Abaco Capital Plc was a drug development company, which was engaged in re-developing approved drugs using proprietary formulation technologies. The company was founded by Marcelo Bravo and Nigel Theobald on October 7, 2009 and was headquartered in London, the United Kingdom. | Finance |
Oxford Pharmascience Ltd.
![]() Oxford Pharmascience Ltd. Pharmaceuticals: MajorHealth Technology Oxford Pharmascience Ltd. operates as a drug development firm. The company was founded on February 8, 2008 and is headquartered in London, the United Kingdom. | Health Technology |
OXvax Ltd
![]() OXvax Ltd BiotechnologyHealth Technology OXvax Ltd is a British company that develops cancer vaccines. The company was founded in 2021 by Paul J. Fairchild, Marcelo Leonardo Bravo, Tim Davies. Marcelo Leonardo Bravo has been the CEO since 2021. | Health Technology |
- Börse
- Insiders
- Marcelo Bravo
- Erfahrung